Web of Pharma · GMP Digital Quality

CSV Validation Life Cycle in Pharmaceuticals

A practical, risk-based guide to planning, validating, operating, changing, and retiring GxP computerized systems.

Content prepared by the Web of Pharma Editorial Team · Regulatory status checked October 2, 2026

Computerized System Validation GxP Lifecycle Risk-Based Assurance Data Integrity

Quick answer: What is the CSV validation life cycle?

The computerized system validation (CSV) life cycle is the controlled set of activities used to show that a computerized system is fit for its intended GxP use and remains in a state of control. It starts with intended use and risk assessment, then moves through requirements, supplier and design review, testing, release, routine operation, change control, periodic review, and retirement. The evidence should be proportionate to risks to patient safety, product quality, and data integrity—not based on a one-size-fits-all test package.

Start with intended useDefine the regulated process, records, users, interfaces, and decisions that depend on the system.

Scale evidence to riskUse documented, science-based risk assessment to focus controls and testing on meaningful failure modes.

Maintain validated stateRelease is a milestone, not the end. Manage changes, access, incidents, backups, reviews, and supplier services.

Prove traceabilityConnect approved requirements to risk controls, tests, results, deviations, and release decisions.

A spreadsheet used to trend noncritical data and a laboratory information management system (LIMS) supporting release decisions do not carry the same risk. A sound CSV life cycle makes that distinction explicit while preserving consistent governance, reliable records, and clear accountability.

What does CSV mean in pharmaceutical manufacturing?

CSV is the documented approach for establishing and maintaining confidence that a computerized system performs its intended function consistently in a regulated process. The system boundary may include application software, configured workflows, infrastructure, interfaces, data, user roles, reports, and procedures—not just the software package.

Validation is not simply a collection of test scripts. It combines requirements, risk controls, supplier evidence, configuration and infrastructure controls, verification, user procedures, data governance, and ongoing oversight. The validation package should tell a clear story: what the system is used for, what could go wrong, what controls prevent or detect those failures, and what objective evidence shows those controls work.

CSV should be integrated with the pharmaceutical quality system and cGMP. It also supports broader computerized system validation practices across laboratory, manufacturing, quality, warehouse, and business applications.

Which regulations and guidance shape the CSV life cycle?

There is no single universal CSV protocol that applies unchanged to every application. The organization should identify the laws, GMP requirements, guidance, and commitments relevant to the system’s intended use, market, records, and business process.

Source	How it informs CSV	Practical interpretation
EU GMP Annex 11	Applies to computerized systems used in GMP-regulated activities and addresses risk management, validation, suppliers, data, security, audit trails, change control, periodic evaluation, and continuity.	Validate the application, qualify IT infrastructure, cover relevant lifecycle steps, and justify the scope and depth of evidence.
21 CFR Part 11	Applies to certain electronic records and signatures when the records are within the rule’s scope; §11.10 includes validation and controls for closed systems.	Determine applicability record by record and process by process. Design for trustworthy records, access control, audit trails, retrieval, and signature accountability where applicable.
U.S. drug CGMP, including 21 CFR 211.68	Addresses automatic, mechanical, and electronic equipment, routine checks, written programs, records, authorized changes, input/output accuracy, and backup controls.	Connect software controls to the applicable drug CGMP process and documented records. Part 11 does not replace predicate-rule obligations.
ICH Q9(R1)	Describes quality risk management as a process for assessing, controlling, communicating, and reviewing risk across the product lifecycle.	Use a risk method that is scientifically grounded and proportionate to impact; revisit risks when knowledge or the system changes.
FDA software validation guidance and CSA guidance	Offer FDA recommendations for software validation; the 2026 CSA guidance is specifically for software used in medical-device production or the medical-device quality management system.	Do not treat the medical-device CSA guidance as a replacement for pharmaceutical GMP CSV obligations. Its principles may inform a broader risk-based discussion, but scope must be justified.

Regulatory status note: As checked on 2 October 2026, the European Commission’s EudraLex Volume 4 listing identifies Annex 11 as the January 2011 revision. A revised Annex 11 was consulted on in 2025, but the consultation page is marked closed; its draft provisions should not be presented as operative requirements unless and until formally adopted and brought into effect.

For U.S.-regulated systems, 21 CFR requirements should be read with the relevant predicate rules and FDA’s Part 11 scope guidance. A documented applicability assessment helps avoid both under-control and unnecessary blanket controls.

Core principles of a defensible CSV life cycle

• Intended use first: Define what regulated activity the system supports and how its outputs are used.
• Risk-based rigor: Set validation depth based on risk to patients, product quality, process control, and record integrity.
• Lifecycle ownership: Assign accountable process, system, quality, IT, and supplier roles before the system is implemented.
• Requirements traceability: Link each relevant user requirement to risks, controls, test evidence, and deviations.
• Data integrity by design: Protect complete, accurate, attributable, legible, contemporaneous, original, and enduring records. See the guide to ALCOA+.
• Controlled change: Assess and approve changes before implementation, with testing and documentation proportionate to impact.
• Evidence that can be inspected: Keep controlled records, clear decisions, and readable exports available throughout retention.
• Ongoing verification: Reassess performance, risk controls, supplier services, and validated state during routine operation.

CSV validation life cycle at a glance

Lifecycle stage	Main question	Typical controlled evidence
1. Governance and inventory	Who owns the system and is it in scope?	System inventory, system owner, process owner, GxP impact assessment, validation policy.
2. Intended use and planning	What must the system do, and how will assurance be achieved?	Intended-use statement, system boundary, validation plan, roles, risk method, deliverable list.
3. Risk and requirements	What failures matter and what controls are needed?	Risk assessment, approved URS, data-flow and interface requirements, traceability approach.
4. Supplier, design, and configuration	Can the selected solution meet requirements under controlled conditions?	Supplier assessment, specifications, configuration records, design reviews, infrastructure qualification evidence.
5. Verification and qualification	Does the implemented system meet critical requirements?	Approved protocols, test evidence, IQ/OQ/PQ where applicable, trace matrix, deviation records.
6. Release and operation	Can trained users operate the approved system reliably?	Summary report, release approval, training, procedures, access, backup, support, and contingency records.
7. Maintenance and review	Does the system remain fit for use after changes and over time?	Change control, incident/CAPA records, periodic review, supplier oversight, requalification rationale.
8. Retirement and migration	Can regulated records remain complete, readable, and retrievable?	Decommissioning plan, archive verification, migration reconciliation, access closure, final report.

Step-by-step CSV validation life cycle

1. Establish governance, ownership, and the system inventory

Begin with a controlled inventory of computerized systems used in GxP processes. For each system, record a unique identifier, business process, site, owner, supplier, hosting model, interfaces, data types, intended use, lifecycle status, and preliminary criticality.

Assign a process owner who understands the regulated activity and a system owner who is accountable for technical availability, maintenance, and security. Quality Assurance (QA) provides independent oversight; IT or engineering manages infrastructure and technical controls; users and subject-matter experts define practical needs; supplier responsibilities are documented. A useful SOP should explain how these roles interact and how lifecycle records are approved.

The inventory should include the system’s lifecycle state. A system that is planned, under implementation, in routine use, temporarily suspended, or being retired needs different controls and decisions.

2. Define intended use and system boundaries

Describe the system’s purpose in specific operational terms. Avoid a vague statement such as “supports quality.” State which process it supports, what regulated records it creates or changes, what decisions rely on it, and who uses those records.

Map the boundary around the application and relevant dependencies. Consider servers, operating systems, databases, identity services, time sources, interfaces, instruments, reports, spreadsheets, cloud services, and manual steps. Identify where data originate, how they are transformed, where authoritative records reside, and how outputs flow to downstream systems.

This boundary helps prevent two common gaps: validating the application while ignoring its critical infrastructure, or treating every connected IT service as equally critical without a documented rationale.

3. Perform GxP impact and risk assessments

First decide whether the system has a GxP impact. Then assess how failure, misuse, unauthorized change, data loss, or incorrect configuration could affect patient safety, product quality, process control, or required records. Include the likelihood of occurrence and the ability of existing controls to prevent or detect the issue.

Risk assessment should identify functions and data that need controls, not merely assign a label to the whole application. In a LIMS, for example, specification limits, result calculations, sample status, review, and audit-trail functions may have different criticality.

Example function	Potential failure	Possible impact	Assurance focus
LIMS result calculation	Incorrect formula or unit conversion	Invalid laboratory result or release decision	Formula verification, boundary values, units, independent calculation, change controls.
Electronic batch record	Unauthorized step completion or missing check	Uncontrolled execution or incomplete batch evidence	Role permissions, sequence checks, signature meaning, audit trails, exceptions.
Read-only training dashboard	Delayed refresh or display error	Usually limited to information display, depending on use	Confirm source, intended use, downstream decision reliance, and proportionate monitoring.
Archive/retrieval service	Record cannot be retrieved or rendered accurately	Inspection, investigation, or retention failure	Restore/retrieval tests, export readability, metadata, retention and access controls.

Use the site’s approved quality risk management method. A numerical risk priority number can help organize analysis, but a single score should not hide a severe patient or data-integrity consequence. Record assumptions, controls, residual risk, approvers, and review triggers. ICH Q9(R1) supports effort and formality proportionate to risk; it does not prescribe one universal CSV scoring scale.

4. Write and approve requirements

Translate intended use into clear, testable user requirements. A good requirement says what the system must do and how success will be recognized. It should avoid design choices unless the design itself is necessary to meet a business, safety, or compliance need.

Requirements commonly cover:

• Workflow steps, statuses, and permitted sequencing.
• Calculations, limits, rounding, units, and data validation.
• User roles, access rights, segregation of duties, and approvals.
• Electronic records, signatures, audit trails, and record copies where applicable.
• Interfaces, data ownership, error handling, reconciliation, and time synchronization.
• Reports, search, retention, export, restore, and inspection readability.
• Availability, performance, security, backup, disaster recovery, and contingency procedures.
• Training, operating procedures, and support expectations.

Each requirement should have a unique identifier, rationale, risk linkage where appropriate, acceptance criteria, and planned verification method. Keep requirements traceable through design, configuration, testing, deviations, and release. A clear URS is the anchor for that traceability.

5. Assess suppliers and use supplier evidence appropriately

Supplier documentation can reduce duplicated work, but it does not transfer the regulated company’s responsibility for the system’s use. Assess supplier competence and reliability in proportion to system risk and service criticality.

Review relevant evidence such as quality management practices, development and release controls, defect management, security practices, support model, service continuity, subcontractors, audit reports, and change notifications. For hosted services, understand data location and ownership, backup and recovery, service availability, incident notification, access by provider staff, audit rights, retention, export, and exit or migration support.

Document what supplier evidence is accepted, what must be supplemented locally, and why. Review configuration and intended use in the regulated environment. Ensure contracts or quality agreements define responsibilities, service levels, incident escalation, records access, and change communication.

6. Review design, configuration, and infrastructure

Check that the system design and configuration can meet approved requirements and risk controls. For a configurable commercial system, review the selected modules, workflows, parameters, roles, reports, calculations, and interfaces. For custom software, include appropriate lifecycle controls over specification, code, review, build, testing, and release.

Infrastructure qualification addresses the hardware and software platform that enables the application to function. Its scope may include servers, network components, databases, operating systems, virtualization, cloud hosting, time services, and backup environments. The depth of evidence depends on the architecture and risk, including supplier controls and shared responsibilities.

Maintain controlled records of configuration baselines, environment versions, interface maps, design decisions, and deviations from the approved design. Link relevant design controls to DQ and installation evidence to IQ where those qualification stages are used.

7. Plan and execute verification and qualification testing

Testing should demonstrate that the configured system satisfies relevant requirements and risk controls. Define test scope, environments, prerequisites, test data, expected results, acceptance criteria, responsibilities, defect handling, and retesting before execution.

Choose methods that produce reliable evidence. Depending on risk, this may include scripted testing, unscripted exploratory testing with documented objectives and observations, supplier testing review, automated testing, inspection, calculation checks, or other justified methods. The method should make the result and the tester’s conclusion clear.

Test scenarios should challenge more than the successful path. Consider:

• Normal and expected user workflows.
• Invalid, incomplete, duplicate, out-of-range, and boundary inputs.
• Calculations, units, rounding, limits, and report values.
• Role restrictions, permissions, approval paths, and segregation of duties.
• Audit-trail creation, review, and preservation of prior values where applicable.
• Electronic-signature identity, meaning, and record linkage where applicable.
• Interfaces, transmission failures, reconciliation, retries, and duplicate prevention.
• Backup, restoration, archive, retrieval, and readable record copies.
• Configuration errors, alarms, exception handling, and recovery.

Installation, operational, and performance qualification are useful structures where appropriate, but the terms do not mean every software system must follow identical IQ/OQ/PQ scripts. Define the purpose and scope for each test stage, or use a justified alternative. See the related guides to OQ and PQ.

Record actual results as they occur. Preserve test evidence, system version, environment, tester identity, date, references to requirements, and any issue raised. Do not silently correct a failed result or delete an unexpected outcome.

8. Manage deviations and decide readiness for release

Investigate test failures and unexpected results under the quality system. Determine the cause, evaluate the effect on requirements and other functions, document correction and retest, and assess whether risk has changed. A failure is not automatically resolved by a successful rerun; the original result and investigation remain part of the record.

Before release, verify that:

• Critical requirements have acceptable evidence and traceability.
• High-risk defects are resolved or have an approved, justified disposition.
• Required data-integrity controls are in place.
• Procedures, training, access, support, backup, and contingency measures are ready.
• Residual risks are understood and formally accepted by appropriate roles.
• The validation summary states the system version, scope, results, deviations, limitations, and release recommendation.

QA approval should follow the site’s quality system. A signed report cannot make an inadequate test adequate; the evidence and reasoning must support the release decision.

9. Operate the system under controlled procedures

After release, users should work only within approved roles and procedures. Routine controls may include account provisioning and removal, access reviews, training, incident reporting, backup monitoring, audit-trail review, data review, interface monitoring, and supplier service oversight.

Write procedures for system use, administration, security, configuration, backup and restoration, incident handling, business continuity, and record retention as appropriate. Keep responsibilities and escalation paths clear. User-facing procedures should describe what staff must do when the system is unavailable, data appear incorrect, an interface fails, or an unexpected result occurs.

Electronic records and signatures must remain accurate, available, and attributable throughout retention. Where Part 11 applies, keep controls aligned with relevant provisions. Good records practice also depends on ALCOA+ principles and effective data governance.

10. Control changes, incidents, and periodic review

Changes may come from a supplier upgrade, configuration adjustment, security patch, new interface, revised workflow, infrastructure migration, or business-process change. Before implementation, assess the effect on intended use, requirements, risks, data, interfaces, access, records, and validated state. Set regression testing and approval based on that assessment.

Incidents and deviations can reveal that a control is ineffective or that the original risk assessment missed a failure mode. Investigate, assess affected records and product decisions, and open CAPA when warranted. Trend recurring issues rather than treating each event as isolated.

A periodic review should confirm that the system remains fit for intended use. Review significant changes, incidents, access, audit-trail reviews, backup and restore results, supplier performance, security events, open risks, training, procedures, and record retrieval. Frequency should be justified by criticality, use, changes, and site policy; no single interval fits every system.

11. Retire the system and preserve regulated records

Retirement needs controlled planning. Identify required records and retention periods, archive or migration destination, formats, metadata, relationships, readability, retrieval method, access controls, and responsibilities. Test the migration or archive to show that records remain complete and usable.

Reconcile source and target record counts or other appropriate control totals. Confirm that signatures, audit-trail context, timestamps, attachments, and links remain available where needed. Restrict or remove access to the retired application, retain necessary documentation, and close supplier services only after records and continuity needs are addressed.

How to use risk assessment to scale CSV evidence

A practical risk assessment begins with a clear question: if this function fails or is misused, what could happen to patients, product quality, process control, or required records? Then identify existing controls and decide what evidence is needed to show the residual risk is acceptable.

1. Map the process: Identify decisions, records, users, and data flows that depend on the system.
2. Identify failure modes: Include wrong values, missing steps, unauthorized changes, incorrect calculations, interface errors, loss, or inability to retrieve records.
3. Evaluate impact and detectability: Consider severity and whether routine controls would prevent or detect the issue before harm.
4. Define controls: Add system, procedural, supplier, or monitoring controls that address each meaningful risk.
5. Choose evidence: Select tests, reviews, supplier records, and operational checks that directly verify the controls.
6. Review residual risk: Record the rationale, approvers, assumptions, and triggers for reassessment.

Risk-based validation does not mean “less documentation” by default. It means documentation is focused on risk and explains why selected controls and tests provide enough confidence.

Worked example: CSV life cycle for a laboratory LIMS

Consider a LIMS that registers samples, assigns tests, records results, calculates values, routes review, and supports release decisions. The organization first defines its intended use and system boundary, including instrument interfaces, specification data, calculations, review workflows, electronic signatures, and report outputs.

Risk or requirement	Control or test example	Evidence to retain
Sample identity must remain linked to the correct test	Challenge sample creation, label generation, reassignment restrictions, duplicate IDs, and interface mapping.	Approved requirement, test case, actual results, traceability link, any deviation and retest.
Calculation must be correct across its operating range	Compare selected values with an independently verified calculation, including boundary and unit-conversion cases.	Calculation rationale, approved expected values, source data, test record, reviewer approval.
Only authorized roles may approve results	Test allowed and prohibited actions for analyst, reviewer, administrator, and QA roles.	Role matrix, account configuration evidence, positive/negative test results, access SOP.
Changes to results must be attributable	Verify the system captures original value, changed value, user, date/time, and reason as configured and required.	Audit-trail test evidence, procedure for review, sample review record.
Records must be available during an outage or archive period	Test backup restoration or record retrieval using representative records and readable output.	Approved recovery criteria, restore or retrieval results, reconciliation, archive procedure.

The team then resolves deviations, confirms requirements traceability, trains users, approves operating procedures, reviews residual risks, and issues a release report. During routine use, upgrades and changes are assessed before implementation. Periodic review confirms ongoing suitability. This example is illustrative; a real protocol must use the system’s configuration, approved limits, and site quality system.

CSV documents and records to maintain

The exact document set should match system risk, complexity, supplier evidence, and applicable regulations. A typical file may contain:

• System inventory entry and GxP impact assessment.
• Validation plan or project strategy, roles, and approvals.
• Intended-use statement, system boundary, process map, and data-flow diagram.
• Documented risk assessment and risk-control traceability.
• Approved URS and functional/configuration specifications as needed.
• Supplier assessment, service agreements, and supplier evidence evaluation.
• Design/configuration records, environment baseline, and infrastructure qualification evidence.
• Approved test protocols, executed records, traceability matrix, and test data controls.
• Deviation, defect, change, and corrective-action records.
• Validation summary, residual-risk decision, and release approval.
• Operating, administrator, security, backup, restore, continuity, and archive procedures.
• Training, access, periodic review, incident, and supplier-performance records.
• Retirement, migration, archive, and final decommissioning records.

Records should follow controlled documentation practices and be attributable, legible, contemporaneous, original or true copy, accurate, complete, consistent, enduring, and available. Where electronic records and signatures are used, assess relevant 21 CFR obligations and retain evidence in an inspection-ready form.

Common CSV life cycle mistakes to avoid

• Starting with templates instead of intended use: Generic scripts may miss real process and data risks.
• Calling every system either “GxP” or “non-GxP” without analysis: Different functions and records can carry different levels of impact.
• Testing only the happy path: Invalid inputs, role restrictions, failures, interfaces, audit trails, and recovery matter too.
• Copying supplier tests without review: Supplier evidence must be relevant to the configured system and intended use.
• Equating IQ/OQ/PQ with complete validation: Qualification labels do not replace requirements, risk controls, data integrity, or lifecycle management.
• Ignoring spreadsheets and interfaces: A connected component or manual transfer can create a critical data risk.
• Accepting a successful retest without investigating the original failure: Preserve the original evidence and assess impact.
• Stopping at go-live: Access, changes, incidents, backups, suppliers, review, and retirement all sustain the validated state.
• Applying Part 11 indiscriminately: Determine the scope of required electronic records and signatures instead of labeling every digital item the same way.
• Treating draft guidance as binding: Distinguish regulations and currently applicable GMP from draft proposals and nonbinding guidance.

CSV readiness checklist for an audit

• The system is listed with a named process owner and system owner.
• Intended use, system boundary, interfaces, and regulated records are documented.
• GxP impact and risk assessments have rationale, approvals, and review triggers.
• Critical user requirements are testable and traceable to controls and evidence.
• Supplier and service-provider responsibilities are assessed and documented.
• System configuration and relevant infrastructure baselines are controlled.
• Tests include critical workflows, negative paths, data integrity, roles, interfaces, and recovery as appropriate.
• Deviations, defect decisions, retests, and residual risks are documented.
• Release approval is supported by a summary report and complete evidence.
• Users and administrators are trained; operating and contingency procedures are current.
• Access, audit trails, backups, incidents, changes, and suppliers are managed during operation.
• Periodic review and retirement plans protect continued record availability and readability.

Frequently asked questions about the CSV validation life cycle

1. What is the CSV validation life cycle?

It is the controlled lifecycle used to establish and maintain documented confidence that a computerized system is fit for its intended GxP use. It covers planning, requirements, risk assessment, implementation, verification, release, operation, change, periodic review, and retirement.

2. What are the main phases of pharmaceutical CSV?

Common phases are system inventory and governance, intended use, GxP impact and risk assessment, requirements, supplier and design review, configuration and infrastructure qualification, verification testing, release, routine operation, change control, periodic review, and retirement. Sites may organize these phases differently while preserving the required controls and evidence.

3. Is CSV required for every software application in a pharmaceutical company?

No single test package is appropriate for every application. The organization should assess intended use and GxP impact, determine applicable regulatory obligations, and document the rationale for the controls and assurance activities selected. A system with no regulated use may need different oversight from one supporting product release or required records.

4. How does risk-based CSV work?

Risk-based CSV identifies what could go wrong, evaluates potential impact to patient safety, product quality, process control, and data integrity, then selects controls and evidence proportionate to that risk. The risk assessment and its rationale should be documented and revisited when the system or process changes.

5. What is the difference between CSV and software testing?

Software testing checks selected behavior under defined conditions. CSV is broader: it connects intended use and requirements to risk controls, supplier and infrastructure evidence, testing, procedures, training, data governance, release, and ongoing maintenance of the validated state.

6. Are IQ, OQ, and PQ mandatory for every computerized system?

Not necessarily as fixed document names or identical protocols. Qualification stages can be useful to verify installation, operation, and performance, but the company should choose and justify the evidence that demonstrates intended use and critical controls for its system.

7. When should CSV validation begin?

Begin during system selection and planning, before configuration or implementation decisions become difficult to change. Early involvement helps define intended use, risk, requirements, supplier responsibilities, data flows, and test strategy before release activities begin.

8. How often should a validated system be revalidated?

There is no single universal interval for every system. Use periodic review and risk-based triggers such as significant changes, recurring incidents, supplier changes, security events, failed recovery tests, or evidence that controls no longer work. The site procedure should define review criteria and frequency.

9. Does 21 CFR Part 11 apply to every electronic record?

Part 11 applies to electronic records and signatures within its defined scope, including records required by FDA regulations that a company maintains electronically. Assess the applicable predicate rule, the record, how it is maintained or submitted, and whether electronic signatures are used.

10. What happens to CSV evidence when a system is retired?

Retain the validation and lifecycle evidence required by the quality system and applicable retention rules. Plan and test archiving or migration so records remain complete, readable, attributable, retrievable, and protected for the required period; document reconciliation and controlled decommissioning.

Conclusion: keep validation active throughout the system life

A robust CSV validation life cycle links the system’s intended use to risk, requirements, evidence, and controlled operation. It gives teams a reasoned way to decide what to test, how to handle supplier evidence, when a change needs re-verification, and how to preserve records when the system is retired.

Use the lifecycle map and audit checklist as a starting point, then adapt them to the system, applicable market requirements, and your approved quality procedures. For related guidance, explore our articles on Computerized System Validation, ALCOA+ data integrity, and CAPA in pharmaceuticals.

References and further reading

1. European Commission, EudraLex Volume 4: Good Manufacturing Practice — current listing for Annex 11 and the EU GMP framework.
2. European Commission, EU GMP Annex 11: Computerised Systems (revision January 2011).
3. European Commission, 2025 stakeholder consultation on revised Chapter 4, Annex 11, and new Annex 22 — consultation status and draft context.
4. Electronic Code of Federal Regulations, 21 CFR Part 11: Electronic Records; Electronic Signatures.
5. eCFR, 21 CFR §11.10: Controls for closed systems.
6. eCFR, 21 CFR §211.68: Automatic, mechanical, and electronic equipment.
7. FDA, Part 11, Electronic Records; Electronic Signatures—Scope and Application.
8. ICH Q9(R1), Quality Risk Management.
9. FDA, General Principles of Software Validation — medical-device software guidance; use within its stated scope.
10. FDA, Computer Software Assurance for Production and Quality Management System Software (February 2026) — medical-device production and quality-system software guidance.

This educational article summarizes general lifecycle concepts and is not a substitute for applicable regulations, regulatory guidance, legal advice, or a site-approved validation procedure. Confirm current requirements, market scope, and implementation dates before making compliance decisions.